ACROBiosystems Co., Ltd.

ACROBiosystems Co. has shown notable stock performance, gaining 20.0% on August 10, 2026, and achieving a 72.67% increase over the past week. Despite a challenging year with a -32.82% return, key financial metrics indicate a fair valuation in the Pharmaceuticals & Biotechnology sector.

ACROBiosystems Co. has experienced notable stock performance, significantly outperforming the China Shanghai Composite in recent weeks. Despite a challenging year with a negative return, the company reported strong operating cash flow and a decrease in raw material costs, although long-term growth remains a concern.

ACROBiosystems Co. saw a notable stock decline today, contrasting with the broader market's performance. Despite a positive one-month trend, the company has faced challenges over the year and three years. It reported strong operating cash flow and maintains a fair valuation, though its returns have lagged behind the market.

ACROBiosystems Co. has experienced notable stock activity, gaining 5.31% on July 10, 2026, despite a declining market. The company reported strong operating cash flow and a solid debtors turnover ratio, although it faces long-term growth challenges with a decline in operating profit over the past five years.

ACROBiosystems Co. has experienced notable short-term gains, outperforming the China Shanghai Composite significantly. The company reported a 26.33% increase in net sales and strong operating cash flow. However, it has faced challenges over the past year, with a decline in stock value compared to broader market performance.

ACROBiosystems Co., Ltd. has experienced a recent adjustment in its evaluation, reflecting changes in technical and valuation metrics. Key financial indicators show a high P/E ratio and mixed signals in its technical outlook, highlighting the complexities of the company's market position and financial health despite recent sales growth.